Study summary

A myelin-repair drug did not restore function

Myelin repair status · Phase 2 · Reported 2025 to 2026

What was tested

PIPE-307, a pill designed to help the brain rebuild the myelin coating on nerves, in people with MS.

What they found

The drug acted on myelin biology in laboratory models but did not restore function in people.
No myelin-repair treatment has succeeded in a phase 3 trial.

What it means

Repairing damage remains the hardest goal in MS.

Labiotech ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.